Pfizer, Inc. (NYSE:PFE) was downgraded by research analysts at Vetr from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday. They presently have a $35.83 price objective on the biopharmaceutical company’s stock. Vetr‘s target price would suggest a potential upside of 11.86% from the company’s current price. A number of […]
